Revealed by those genomic sequencing approaches, genetic alterations in various genes, such as TP53, EGFR (EGFRvIII mutation), and PDGFR, or hypermethylation of CpG promoters (O-6-Methylguanine-DNA Methyltransferase (MGMT) promoter methylation is a key predictor of response to temozolomide in genes related to tumor formation and progression (64). Here, MGMT is linked to neoplasm.